Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 701 in Late-onset Pompe Disease
NCT01230801Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jan 2011
- Primary completion
- Mar 2013
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of reveglucosidase alfa in Pompe disease, sponsored by BioMarin Pharmaceutical. Primary endpoint: Number of Participants With Adverse Events at 24 weeks. Started Jan 2011; status: completed.
02
Drugs
reveglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT01230801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01230801.